Findings of Research Misconduct, 56042-56043 [2017-25549]
Download as PDF
56042
Federal Register / Vol. 82, No. 226 / Monday, November 27, 2017 / Notices
HRSA specifically requests comments
on (1) the necessity and utility of the
proposed information collection for the
proper performance of the agency’s
functions, (2) the accuracy of the
estimated burden, (3) ways to enhance
the quality, utility, and clarity of the
information to be collected, and (4) the
use of automated collection techniques
or other forms of information
technology to minimize the information
collection burden.
Amy McNulty,
Acting Director, Division of the Executive
Secretariat.
[FR Doc. 2017–25507 Filed 11–24–17; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the Chronic Fatigue
Syndrome Advisory Committee
Office of the Assistant
Secretary for Health, Office of the
Secretary, Department of Health and
Human Services.
ACTION: Notice.
AGENCY:
As stipulated by the Federal
Advisory Committee Act, the U.S.
Department of Health and Human
Services (HHS) is hereby giving notice
that a meeting of the Chronic Fatigue
Syndrome Advisory Committee
(CFSAC) will take place and will be
open to the public.
DATES: The CFSAC in person meeting
will be held on Wednesday, December
13, 2017, from 9:00 a.m. until 3:30 p.m.
and Thursday, December 14, 2017, from
9:00 a.m. until 5:00 p.m. (EST).
ADDRESSES: U.S. Department of Health
and Human Services, Hubert H.
Humphrey Building, Room 800, 200
Independence Avenue SW.,
Washington, DC 20201.
FOR FURTHER INFORMATION CONTACT:
Commander Gustavo Ceinos, MPH,
Designated Federal Officer, Chronic
Fatigue Syndrome Advisory Committee,
Department of Health and Human
Services, 200 Independence Avenue
SW., Room 728F6, Washington, DC
20201. Please direct all inquiries to
cfsac@hhs.gov or 202–690–7650.
SUPPLEMENTARY INFORMATION: The
CFSAC is authorized under 42 U.S.C.
217a, Section 222 of the Public Health
Service Act, as amended. The purpose
of the CFSAC is to provide advice and
recommendations to the Secretary of
Health and Human Services, through
the Assistant Secretary for Health
(ASH), on issues related to myalgic
encephalomyelitis/chronic fatigue
asabaliauskas on DSKBBXCHB2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
16:59 Nov 24, 2017
Jkt 244001
syndrome (ME/CFS). The issues can
include factors affecting access and care
for persons with ME/CFS; the science
and definition of ME/CFS; and broader
public health, clinical, research, and
educational issues related to ME/CFS.
The agenda for this meeting, call-in
information and location will be posted
on the CFSAC Web site https://
www.hhs.gov/ash/advisory-committees/
cfsac/meetings/.
Request to speak to the committee:
Each day of the meeting an hour has
been scheduled for public comments via
telephone or in person. Individuals will
have three minutes to present their
comments. Priority will be given to
individuals who have not provided
public comment within the previous
twelve months. We are unable to place
international calls for public comments.
To request a time slot for public
comments, please send an email to
cfsac@hhs.gov by close of business on
Monday, November 27, 2017. The email
should contain the speaker’s name and
the phone number that will be used for
public comments.
An email from the CFSAC Support
Team will be sent back to you
confirming receipt of your request. If the
email confirmation is not received
within two working days, please call
202–690–7650.
Request to provide written comments:
Individuals who would like to provide
only written testimony to the Committee
members and do not wish to speak,
should indicate so in their email when
submitting their written testimony. It is
preferred, but not required, that the
submitted testimony be prepared in
digital format and typed using a 12pitch font. Written comments must not
exceed 5 single-space pages, and it is
preferred, but not required that the
document be prepared in the MS Word
format. Please note that PDF files,
handwritten notes, charts, and
photographs cannot be accepted.
Materials submitted should not include
sensitive personal information, such as
social security number, birthdates,
driver’s license number, passport
number, financial account number, or
credit or debit card number. If you wish
to remain anonymous please specify
this in your email, otherwise your name
will be included at the top of your
written comments.
The Committee welcomes input on
any topic related to ME/CFS.
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
Dated: November 17, 2017.
Gustavo Ceinos,
CDR, USPHS, Designated Federal Officer,
Chronic Fatigue Syndrome Advisory
Committee.
[FR Doc. 2017–25550 Filed 11–24–17; 8:45 am]
BILLING CODE 4150–42–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
Notice is hereby given that the Office
of Research Integrity (ORI) has taken
final action in the following case:
Mahandranauth Chetram, Ph.D.,
Georgetown University and Emory
School of Medicine: Based on the report
of an investigation conducted by
Georgetown University (GU),
Respondent’s admission at Emory
School of Medicine (ESOM), and
additional analysis conducted by ORI in
its oversight review, ORI found that Dr.
Mahandranauth Chetram, former
postdoctoral fellow, Department of
Oncology, GU, and former postdoctoral
fellow, Department of Pediatrics, ESOM,
engaged in research misconduct in
research supported by National Cancer
Institute (NCI), National Institutes of
Health (NIH), grants R01 CA113447, R01
CA092306, and T32 CA09686 while at
GU, and National Institute of Diabetes
and Digestive and Kidney Diseases
(NIDDK), NIH, grant R01 DK059380
while at ESOM.
ORI found that Respondent engaged
in research misconduct at GU by
falsifying Western blot images and
polymerase chain reaction (PCR) data
included in an unfunded grant
application, R01 CA193344–01A1, and
in a manuscript submitted to Cancer
Cell (‘‘The DNA Repair Protein, NTHL1
Functions as an Oncoprotein by
Activating the Canoncial Wnt Pathway.’’
Submitted to Cancer Cell; hereafter
referred to as the ‘‘Cancer Cell
manuscript’’). Subsequently, after
Respondent was aware of the research
misconduct findings from GU,
Respondent engaged in research
misconduct at ESOM and falsified RT–
PCR data on Excel spreadsheets in the
research record and in a figure
generated from the false data included
in a manuscript submitted to and
withdrawn from Scientific Reports
(‘‘Immipramine Blue Sensitively and
Selectively Targets FLT3–ITD Positive
Acute Myeloid Leukemia Cells.’’
Scientific Reports 7(1):4447, 2017 June
E:\FR\FM\27NON1.SGM
27NON1
Federal Register / Vol. 82, No. 226 / Monday, November 27, 2017 / Notices
30; doi:10.1038/s41598–017–04796–1.
PMID: 28667329. Submitted to
Scientific Reports [withdrawn];
hereafter referred to as the ‘‘Scientific
Reports manuscript’’).
Specifically, ORI found:
• While at GU, Respondent falsified
Western blot images and qPCR
experiments examining mechanisms
underlying the hypothesis that the DNA
repair protein, NTHL–1, regulates
wingless signaling in cancer cells. False
Western blot images were included in
Figures 6A and S7L in the Cancer Cell
manuscript, and the same Figure 6A
was included as Figure 8A in grant
application R01 CA193344–01A1. False
qPCR data were included in Figures 3F
and 5D in the Cancer Cell manuscript
and Figures 5C (MCF7 panel) and 5E of
grant application R01 CA193344–01A1.
• While at ESOM, Respondent
falsified data on Excel spreadsheets for
eight (8) RT–PCR experiments
measuring the expression of various
genes in leukemia cell lines and
included false data in the Scientific
Reports manuscript.
Dr. Chetram entered into a Voluntary
Exclusion Agreement and voluntarily
agreed for a period of three (3) years,
beginning on October 19, 2017:
(1) To exclude himself from any
contracting or subcontracting with any
agency of the United States Government
and from eligibility for or involvement
in nonprocurement programs of the
United States Government referred to as
‘‘covered transactions’’ pursuant to
HHS’ Implementation (2 CFR part 376 et
seq.) of OMB Guidelines to Agencies on
Governmentwide Debarment and
Suspension, 2 CFR part 180 (collectively
the ‘‘Debarment Regulations’’); and
(2) To exclude himself voluntarily
from serving in any advisory capacity to
PHS including, but not limited to,
service on any PHS advisory committee,
board, and/or peer review committee, or
as a consultant.
FOR FURTHER INFORMATION CONTACT:
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Director, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8200.
Kathryn M. Partin,
Director, Office of Research Integrity.
[FR Doc. 2017–25549 Filed 11–24–17; 8:45 am]
BILLING CODE 4150–31–P
VerDate Sep<11>2014
16:59 Nov 24, 2017
Jkt 244001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Eye Institute; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Advisory Eye
Council.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications
and/or contract proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Eye Council.
Date: January 18, 2018.
Open: 8:30 a.m. to 1:00 p.m.
Agenda: Following opening remarks by the
Director, NEI, there will be presentations by
the staff of the institute and discussions
concerning Institute programs.
Place: Fishers Lane Conference Center,
Terrace Level, 5635 Fishers Lane, Rockville,
MD 20852.
Closed: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Fishers Lane Conference Center,
Terrace Level, 5635 Fishers Lane, Rockville,
MD 20852.
Contact Person: Paul A. Sheehy, Ph.D.,
Executive Secretary, Division of Extramural
Affairs, National Eye Institute, National
Institutes of Health, 5635 Fishers Lane, Suite
12300, Bethesda, MD 20892, 301–451–2020,
ps32h@nih.gov.
Information is also available on the
Institute’s/Center’s home
page:www.nei.nih.gov, where an agenda and
any additional information for the meeting
will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.867, Vision Research,
National Institutes of Health, HHS)
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
56043
Dated: November 20, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–25449 Filed 11–24–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Environmental
Health Sciences; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Environmental Health Sciences Special
Emphasis Panel, SBIR E-Learning Review.
Date: December 4, 2017.
Time: 11:00 a.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: NIEHS/National Institutes of Health,
Keystone Building, 530 Davis Drive, Room
3118, Research Triangle Park, NC 27709
(Teleconference).
Contact Person: Janice B Allen, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research and
Training, Nat. Institute of Environmental
Health Science, P. O. Box 12233, MD EC–30/
Room 3170, B Research Triangle Park, NC
27709, 919/541–7556, allen9@niehs.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of
Environmental Health Sciences Special
Emphasis Panel Assay Development:
Toxicity Testing with Differentiated Cells
Special Emphasis Panel Review.
Date: December 5, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: NIEHS/National Institutes of Health,
Keystone Building, 530 Davis Drive, Research
Triangle Park, NC 27713 (Virtual Meeting).
Contact Person: Leroy Worth, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research and
Training, Nat. Institute of Environmental
Health Sciences, P. O. Box 12233, MD EC–
E:\FR\FM\27NON1.SGM
27NON1
Agencies
[Federal Register Volume 82, Number 226 (Monday, November 27, 2017)]
[Notices]
[Pages 56042-56043]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-25549]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
Notice is hereby given that the Office of Research Integrity (ORI)
has taken final action in the following case:
Mahandranauth Chetram, Ph.D., Georgetown University and Emory
School of Medicine: Based on the report of an investigation conducted
by Georgetown University (GU), Respondent's admission at Emory School
of Medicine (ESOM), and additional analysis conducted by ORI in its
oversight review, ORI found that Dr. Mahandranauth Chetram, former
postdoctoral fellow, Department of Oncology, GU, and former
postdoctoral fellow, Department of Pediatrics, ESOM, engaged in
research misconduct in research supported by National Cancer Institute
(NCI), National Institutes of Health (NIH), grants R01 CA113447, R01
CA092306, and T32 CA09686 while at GU, and National Institute of
Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, grant R01
DK059380 while at ESOM.
ORI found that Respondent engaged in research misconduct at GU by
falsifying Western blot images and polymerase chain reaction (PCR) data
included in an unfunded grant application, R01 CA193344-01A1, and in a
manuscript submitted to Cancer Cell (``The DNA Repair Protein, NTHL1
Functions as an Oncoprotein by Activating the Canoncial Wnt Pathway.''
Submitted to Cancer Cell; hereafter referred to as the ``Cancer Cell
manuscript''). Subsequently, after Respondent was aware of the research
misconduct findings from GU, Respondent engaged in research misconduct
at ESOM and falsified RT-PCR data on Excel spreadsheets in the research
record and in a figure generated from the false data included in a
manuscript submitted to and withdrawn from Scientific Reports
(``Immipramine Blue Sensitively and Selectively Targets FLT3-ITD
Positive Acute Myeloid Leukemia Cells.'' Scientific Reports 7(1):4447,
2017 June
[[Page 56043]]
30; doi:10.1038/s41598-017-04796-1. PMID: 28667329. Submitted to
Scientific Reports [withdrawn]; hereafter referred to as the
``Scientific Reports manuscript'').
Specifically, ORI found:
While at GU, Respondent falsified Western blot images and
qPCR experiments examining mechanisms underlying the hypothesis that
the DNA repair protein, NTHL-1, regulates wingless signaling in cancer
cells. False Western blot images were included in Figures 6A and S7L in
the Cancer Cell manuscript, and the same Figure 6A was included as
Figure 8A in grant application R01 CA193344-01A1. False qPCR data were
included in Figures 3F and 5D in the Cancer Cell manuscript and Figures
5C (MCF7 panel) and 5E of grant application R01 CA193344-01A1.
While at ESOM, Respondent falsified data on Excel
spreadsheets for eight (8) RT-PCR experiments measuring the expression
of various genes in leukemia cell lines and included false data in the
Scientific Reports manuscript.
Dr. Chetram entered into a Voluntary Exclusion Agreement and
voluntarily agreed for a period of three (3) years, beginning on
October 19, 2017:
(1) To exclude himself from any contracting or subcontracting with
any agency of the United States Government and from eligibility for or
involvement in nonprocurement programs of the United States Government
referred to as ``covered transactions'' pursuant to HHS' Implementation
(2 CFR part 376 et seq.) of OMB Guidelines to Agencies on
Governmentwide Debarment and Suspension, 2 CFR part 180 (collectively
the ``Debarment Regulations''); and
(2) To exclude himself voluntarily from serving in any advisory
capacity to PHS including, but not limited to, service on any PHS
advisory committee, board, and/or peer review committee, or as a
consultant.
FOR FURTHER INFORMATION CONTACT: Director, Office of Research
Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240)
453-8200.
Kathryn M. Partin,
Director, Office of Research Integrity.
[FR Doc. 2017-25549 Filed 11-24-17; 8:45 am]
BILLING CODE 4150-31-P